These in vitro and in vivo results suggest that toxicarioside A treatment can significantly inhibit endoglin expression in tumor angiogenesis-related cells, such as HUVECs, but not in tumor cells (CT26 and LL/2). This evidence concerns the gene ENG and neoplasm.